Publications by authors named "L Connelly-Smith"
Since 2005, there has been a steady decline in chronic graft-versus-host disease (cGVHD) at the Fred Hutchinson Cancer Center. To better understand this phenomenon, we studied the risk of cGVHD requiring systemic immunosuppression (cGVHD-IS) as a function of hematopoietic cell transplantation (HCT) date in 3066 survivors from 2005 through 2019. Cox regression models were fit to assess associations of HCT date (as a continuous linear variable) with cause-specific hazards of cGVHD using unadjusted and adjusted models.
View Article and Find Full Text PDFData on recent bone marrow harvest (BMH) collections from the NMDP has shown that bone marrow (BM) quality has decreased based on total nucleated cell count in the product. To ensure that quality BM products are available to all recipients, the NMDP Marrow Alliance was formed in April 2021 to increase the capability of BM collection centers to safely deliver high-quality products consistently and to identify and disseminate guidelines for performing BMH. This white paper describes the best practices for BMH as defined by the NMDP Marrow Alliance.
View Article and Find Full Text PDFArticle Synopsis
- Physicians aim to cure underlying diseases in patients undergoing hematopoietic cell transplantation (HCT), but ultimately focus on enhancing the survivors' quality of life, particularly through supporting their return to work (RTW).
- A survey of 994 post-HCT survivors revealed that while many had worked before their diagnosis, only 53% were currently employed, with factors like type of HCT and employer support influencing their ability to return to work.
- Despite 95% of respondents expressing a need for RTW support from their transplant centers, only 13% had received such assistance, highlighting a gap in resources and information on available support and benefits for survivors.
Article Synopsis
- Extracorporeal photopheresis (ECP) is a treatment for conditions like cutaneous T-cell lymphoma and relies on anticoagulants to prevent clotting; heparin is preferred, but acid citrate dextrose-A (ACDA) is also used.
- A study compared the performance of these two anticoagulants across 23,334 treatment sessions, analyzing overall treatment time, buffy coat collection time, photoactivation time, and alarm occurrences.
- Results showed that both anticoagulants led to similar treatment durations, but ACDA had less variability in photoactivation time and reduced treatment duration in automatic sessions, indicating it might be a beneficial alternative to heparin.
Introduction: The success of autologous stem cell transplantation (ASCT) for treating non-Hodgkin's lymphoma (NHL) is limited by its high relapse rates. To reduce the risk of relapse, additional maintenance therapy can be added post-transplant. In a non-transplant setting at the time of initiation of this study, both bortezomib and vorinostat had been studied alone or in combination for some NHL histology and showed some clinical activity.
View Article and Find Full Text PDF